{
  "ticker": "AFP",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02975668",
  "id": "02975668",
  "pages": 30,
  "price_sensitive": false,
  "date": "20250801",
  "time": "0730",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250801/pdf/06mdx0kbh3x5mq.pdf",
  "summary": "### Summary of ASX Announcement: **AFT Pharmaceuticals 2025 Annual Shareholders' Meeting Presentation**  \n\n#### **Key Financial Highlights**  \n- **FY25 Revenue**: NZ$208.0M (+6% YoY), with 5-year CAGR of 14%.  \n- **ANZ Sales**: NZ$180.9M (87% of total).  \n- **Operating Profit**: NZ$17.6M (down from NZ$24.2M in FY24) due to lower license income and strategic investments.  \n- **Dividend**: 1.8cps (up from 1.6cps in FY24).  \n- **Net Debt**: NZ$14.5M (down from NZ$16.2M in FY24).  \n- **FY27 Target**: Revenue of NZ$300M.  \n\n#### **Operational & Strategic Updates**  \n- **International Expansion**:  \n  - Products sold in ~80 countries; active R&D pipeline of 8 patented products.  \n  - Launches in UK/EU (Combogesic IV), North America, Asia, and Africa.  \n- **R&D Progress**:  \n  - 24+ injectable products and 5 commercialized R&D programs; key focus on Maxigesic variants (oral/IV) and dermatology (Crystaderm).  \n- **Market-Specific Performance**:  \n  - **Australia**: +17% growth (eyecare/pain relief).  \n  - **Asia**: Disrupted by Korean doctors\u2019 strike.  \n\n#### **Outlook**  \n- FY26 operating profit guidance: NZ$20M\u2013NZ$24M.  \n- Focus on geographic and product diversification to drive growth.  \n\n**No capital raising, trading halt, or material M&A disclosed.**",
  "usage": {
    "prompt_tokens": 5861,
    "completion_tokens": 371,
    "total_tokens": 6232,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-31T22:17:13.437710"
}